Evaluation of sequential effect of isotretinoin on the haematological parameters in patients with acne vulgaris

dc.contributor.authorGencoglan G.
dc.contributor.authorInanir I.
dc.contributor.authorMiskioglu M.
dc.contributor.authorGunduz K.
dc.date.accessioned2024-07-22T08:09:59Z
dc.date.available2024-07-22T08:09:59Z
dc.date.issued2018
dc.description.abstractPurpose: Isotretinoin is the most effective drug for acne with some side effects. Few studies exist regarding the effects of isotretinoin on haematological parameters with different results. Mostly, baseline values with a single value during or at the end of the treatment were compared. In this study, we aimed to determine the differences in haematological parameters during isotretinoin treatment until reaching the cumulative dose of 120 mg/kg. Materials and methods: The study included 118 patients with moderate-to-severe acne vulgaris. Patients with preexisting liver disease, anaemia, iron deficiency, abnormal liver function tests, thrombocytopenia/thrombocytosis or hyperlipidaemia were excluded. Laboratory monitoring for haematological parameters was performed at baseline and monthly during treatment. Parameters at the baseline, at the first and second months and at the end of the therapy were taken into account. Results: According to general linear model analysis, platelets and plateletcrit increased at the first month of the treatment and then decreased to baseline. White blood cells and neutrophils decreased at the first month, then increased to baseline value at the second month, and were found to be decreased again at the end of the treatment. Mean corpuscle volume was found to be increased at the end of the treatment. Other parameters in CBC did not show statistically significant differences. Conclusions: Although some changes occur in haematological parameters during isotretinoin therapy, all of these changes remain within the normal range. Evaluating the spot values at any time during treatment may cause misinterpretations. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.DOI-ID10.1080/15569527.2017.1359837
dc.identifier.issn15569527
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15038
dc.language.isoEnglish
dc.publisherTaylor and Francis Ltd
dc.subjectAcne Vulgaris
dc.subjectAdolescent
dc.subjectAdult
dc.subjectBlood Cell Count
dc.subjectDermatologic Agents
dc.subjectErythrocyte Indices
dc.subjectFemale
dc.subjectHumans
dc.subjectIsotretinoin
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectYoung Adult
dc.subjectisotretinoin
dc.subjectdermatological agent
dc.subjectisotretinoin
dc.subjectacne vulgaris
dc.subjectadolescent
dc.subjectadult
dc.subjectArticle
dc.subjectdisease severity
dc.subjectdrug effect
dc.subjectevaluation study
dc.subjectfemale
dc.subjecthematocrit
dc.subjecthematological parameters
dc.subjecthuman
dc.subjectleukocyte
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmean corpuscular hemoglobin
dc.subjectmean corpuscular volume
dc.subjectneutrophil
dc.subjectacne vulgaris
dc.subjectblood
dc.subjectblood cell count
dc.subjectclinical trial
dc.subjectdrug effect
dc.subjectmiddle aged
dc.subjectyoung adult
dc.titleEvaluation of sequential effect of isotretinoin on the haematological parameters in patients with acne vulgaris
dc.typeArticle

Files